Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Research Article

Non-compliance to Mass Drug Administration Associated with the Low Perception of the Community Members About their Susceptibility to Lymphatic Filariasis in Ankobra, Ghana

Author(s): Ilo Dicko*, Yaya Ibrahim Coulibaly, Modibo Sangaré, Bismark Sarfo and Priscillia Awo Nortey

Volume 20, Issue 2, 2020

Page: [167 - 174] Pages: 8

DOI: 10.2174/1871526519666190206210808

Price: $65

Abstract

Background: Lymphatic filariasis (LF) is a parasitic disease that has been targeted for elimination through the Mass Drug Administration (MDA.) Although the MDA started in the Ankobra community in Ghana in 2000, LF prevalence as reported in 2014 was relatively high (4.5%). Non-compliance to the MDA has been associated with the persistent LF prevalence in endemic regions.

Objective: This study determined the factors associated with the non-compliance to the MDA among patients living in the Ankobra community, Ghana.

Methods: A cross-sectional study using a one-stage cluster sampling method was used to collect data between June and July, 2017 in Ankobra. Questionnaires were used to collect data from health workers, the MDA drug distributors and study participants in Ankobra. Data analysis was performed using STATA 14. Logistic regression was used to measure the degree of association between the dependent (non-compliance) and independent variables. Non-compliance rate was defined as the percentage of individuals who self-reported that they did not actually swallow the drugs provided during the MDA.

Results: The MDA coverage and non-compliance rates were 73.5% (147/200) and 33.33% (49/147) respectively. The main reason for non-compliance was fear of drug adverse events (75.51%, 37/49). Thought of “not being susceptible to LF” was significantly associated with the non-compliance (aOR= 2.83, [CI= 1.15, 6.98]).

Conclusion: Health education about the susceptibility of residents getting LF disease in endemic community must be intensified to improve compliance to MDA medication ingestion and thus meet the Global Elimination of Lymphatic Filariasis by 2020.

Keywords: Lymphatic filariasis, mass drug administration, non-compliance, Ankobra, MDA, susceptibility.

Graphical Abstract
[1]
Global programme to eliminate lymphatic filariasis: progress report. Weekly epidemiological reports (Vol. 38)., 2016.Available from:. http://www.who.int/wer/en/ [Accessed November 15, 2016];
[2]
Ottesen, E.A.; Hooper, P.J.; Bradley, M.; Biswas, G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl. Trop. Dis., 2008, 2(10)e317
[http://dx.doi.org/10.1371/journal.pntd.0000317] [PMID: 18841205]
[3]
Ramaiah, K.D.; Ottesen, E.A. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl. Trop. Dis., 2014, 8(11)e3319
[http://dx.doi.org/10.1371/journal.pntd.0003319] [PMID: 25412180]
[4]
Molyneux, D.H.; Hotez, P.J.; Fenwick, A. “Rapid-impact interventions”: how a policy of integrated control for Africa’s neglected tropical diseases could benefit the poor. PLoS Med., 2005, 2(11)e336
[http://dx.doi.org/10.1371/journal.pmed.0020336] [PMID: 16212468]
[5]
Progress report 2000-2009 and strategic plan 2010-2020 of the global programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic filariasis, 2016.http://www.searo.who.int/entity/vector_borne_tropical_diseases/topics/lymphatic_filariasis/LFREP.pdf2016 [Accessed Decmber 12, 2016];
[6]
Kyelem, D.; Biswas, G.; Bockarie, M.J.; Bradley, M.H.; El-Setouhy, M.; Fischer, P.U.; Henderson, R.H.; Kazura, J.W.; Lammie, P.J.; Njenga, S.M.; Ottesen, E.A.; Ramaiah, K.D.; Richards, F.O.; Weil, G.J.; Williams, S.A. Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs. Am. J. Trop. Med. Hyg., 2008, 79(4), 480-484.
[http://dx.doi.org/10.4269/ajtmh.2008.79.480] [PMID: 18840733]
[7]
de Souza, D.K.; Koudou, B.; Kelly-Hope, L.A.; Wilson, M.D.; Bockarie, M.J.; Boakye, D.A. Diversity and transmission competence in lymphatic filariasis vectors in West Africa, and the implications for accelerated elimination of Anopheles-transmitted filariasis. Parasit. Vectors, 2012, 5, 259.
[http://dx.doi.org/10.1186/1756-3305-5-259] [PMID: 23151383]
[8]
Gyapong, J.O.; Kyelem, D.; Kleinschmidt, I.; Agbo, K.; Ahouandogbo, F.; Gaba, J.; Owusu-Banahene, G.; Sanou, S.; Sodahlon, Y.K.; Biswas, G.; Kale, O.O.; Molyneux, D.H.; Roungou, J.B.; Thomson, M.C.; Remme, J. The use of spatial analysis in mapping the distribution of bancroftian filariasis in four West African countries. Ann. Trop. Med. Parasitol., 2002, 96(7), 695-705.
[http://dx.doi.org/10.1179/000349802125001735] [PMID: 12537631]
[9]
Biritwum, N.K.; de Souza, D.K.; Marfo, B.; Odoom, S.; Alomatu, B.; Asiedu, O.; Yeboah, A.; Hervie, T.E.; Mensah, E.O.; Yikpotey, P.; Koroma, J.B.; Molyneux, D.; Bockarie, M.J.; Gyapong, J.O. Fifteen years of programme implementation for the elimination of Lymphatic Filariasis in Ghana: Impact of MDA on immunoparasitological indicators. PLoS Negl. Trop. Dis., 2017, 11(3)e0005280
[http://dx.doi.org/10.1371/journal.pntd.0005280] [PMID: 28333930]
[10]
Krentel, A.; Fischer, P.U.; Weil, G.J. A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Negl. Trop. Dis., 2013, 7(11)e2447
[http://dx.doi.org/10.1371/journal.pntd.0002447] [PMID: 24278486]
[11]
Nandha, B.; Krishnamoorthy, K.; Jambulingam, P. Towards elimination of lymphatic filariasis: social mobilization issues and challenges in mass drug administration with anti-filarial drugs in Tamil Nadu, South India. Health Educ. Res., 2013, 28(4), 591-598.
[http://dx.doi.org/10.1093/her/cyt042] [PMID: 23503571]
[12]
Hussain, M.A.; Sitha, A.K.; Swain, S.; Kadam, S.; Pati, S. Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infect. Dis. Poverty, 2014, 3, 31.
[http://dx.doi.org/10.1186/2049-9957-3-31] [PMID: 25237478]
[13]
Roy, R.N.; Sarkar, A.P.; Misra, R.; Chakroborty, A.; Mondal, T.K.; Bag, K. Coverage and awareness of and compliance with mass drug administration for elimination of lymphatic filariasis in Burdwan District, West Bengal, India. J. Health Popul. Nutr., 2013, 31(2), 171-177.
[http://dx.doi.org/10.3329/jhpn.v31i2.16380] [PMID: 23930334]
[14]
Senyonjo, L.; Oye, J.; Bakajika, D.; Biholong, B.; Tekle, A.; Boakye, D.; Schmidt, E.; Elhassan, E. Factors associated with ivermectin non-compliance and its potential role in sustaining onchocerca volvulus transmission in the west region of Cameroon. PLoS Negl. Trop. Dis., 2016, 10(8)e0004905
[http://dx.doi.org/10.1371/journal.pntd.0004905] [PMID: 27529622]
[15]
Njomo, D.W.; Amuyunzu-Nyamongo, M.; Magambo, J.K.; Njenga, S.M. The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One, 2012, 7(11)e48395
[http://dx.doi.org/10.1371/journal.pone.0048395] [PMID: 23185256]
[16]
Offei, M.; Anto, F. Bacteriology & parasitology compliance to mass drug administration programme for lymphatic filariasis elimination by community members and volunteers in the ahanta west district of Ghana. J. Bacteriol. Parasitol., 2014, 5, 180.
[17]
Weerasooriya, M.V.; Yahathugoda, C.T.; Wickramasinghe, D.; Gunawardena, K.N.; Dharmadasa, R.A.; Vidanapathirana, K.K.; Weerasekara, S.H.; Samarawickrema, W.A. Social mobilisation, drug coverage and compliance and adverse reactions in a Mass Drug Administration (MDA) Programme for the Elimination of Lymphatic Filariasis in Sri Lanka. Filaria J., 2007, 6, 11.
[http://dx.doi.org/10.1186/1475-2883-6-11] [PMID: 18005398]
[18]
Shuford, K.V.; Turner, H.C.; Anderson, R.M. Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review. Parasit. Vectors, 2016, 9, 29.
[http://dx.doi.org/10.1186/s13071-016-1311-1] [PMID: 26813098]
[19]
Pattanshetty, S.; Kumar, A.; Kumar, R.; Rao, C.R.; Badiger, S.; Rashmi, R.; College, K.M. Mass drug administration to eliminate lymphatic filariasis in Southern India. Australas. Med. J., 2010, 3(13), 847-850.
[http://dx.doi.org/10.4066/AMJ.2010.479]
[20]
Kumar, A.; Kumar, P.; Nagaraj, K.; Nayak, D.; Ashok, L.; Ashok, K. A study on coverage and compliance of mass drug administration programme for elimination of filariasis in Udupi district, Karnataka, India. J. Vector Borne Dis., 2009, 46(3), 237-240.
[PMID: 19724089]
[21]
Cabral, S.; Bonfim, C.; Oliveira, R.; Oliveira, P.; Guimarães, T.; Brandão, E.; Aguiar-Santos, A.M.; Medeiros, Z. Knowledge, attitudes and perceptions regarding lymphatic filariasis: study on systematic noncompliance with mass drug administration. Rev. Inst. Med. Trop. São Paulo, 2017, 59e23
[http://dx.doi.org/10.1590/s1678-9946201759023] [PMID: 28443941]
[22]
Babu, B.V.; Kar, S.K. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop. Med. Int. Health, 2004, 9(6), 702-709.
[http://dx.doi.org/10.1111/j.1365-3156.2004.01247.x] [PMID: 15189460]
[23]
Abd Elaziz, K.M.; El-Setouhy, M.; Bradley, M.H.; Ramzy, R.M.R.; Weil, G.J. Knowledge and practice related to compliance with mass drug administration during the Egyptian national filariasis elimination program. Am. J. Trop. Med. Hyg., 2013, 89(2), 260-264.
[http://dx.doi.org/10.4269/ajtmh.12-0491] [PMID: 23751402]
[24]
Karmakar, P.R.; Mitra, K.; Chatterjee, A.; Jana, P.K.; Bhattacharya, S.; Lahiri, S.K. A study on coverage, compliance and awareness about mass drug administration for elimination of lymphatic filariasis in a district of West Bengal, India. J. Vector Borne Dis., 2011, 48(2), 101-104.
[PMID: 21715733]
[25]
King, J.D.; Zielinski-Gutierrez, E.; Pa’au, M.; Lammie, P. Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Trop., 2011, 120(Suppl. 1), S48-S54.
[http://dx.doi.org/10.1016/j.actatropica.2010.08.021] [PMID: 20932818]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy